-+ 0.00%
-+ 0.00%
-+ 0.00%

Kiniksa Q2 FY26 net income rises 42.7% to $25.4 million; revenue climbs 55.4% to $243.6 million

PUBT·07/28/2026 11:34:34
Listen to the news
Kiniksa Q2 FY26 net income rises 42.7% to $25.4 million; revenue climbs 55.4% to $243.6 million
  • Kiniksa reported Q2 2026 revenue of USD 243.6 million, up about 55% year over year.
  • Net income rose to USD 25.4 million; operating expenses climbed to USD 216.4 million.
  • R&D expenses increased to USD 40.9 million; SG&A costs grew to USD 63.9 million.
  • ARCALYST net product revenue totaled USD 243.6 million; about 21% of 14,000 multiple-recurrence patients were on treatment at quarter-end.
  • 2026 ARCALYST net product revenue outlook lifted to USD 980 million-USD 995 million; KPL-387 Phase 3 PASTORALE is enrolling and dosing patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001730430-26-000031), on July 28, 2026, and is solely responsible for the information contained therein.